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Abstract
Vesicles shed by cancer cells are known to mediate several tumor-host interactions. Tumor microenvironment
may, in turn, influence the release and the activity of tumor-shed microvesicles. In this study, we investigated
the molecular mediators of the pH-dependent proinvasive activity of tumor-shed vesicles. Gelatinase zymography
showed increased microvesicle activity of matrix metalloproteinases 9 and 2 as a result of acid exposure (pH 5.6)
compared to pH 7.4. Thus, we reasoned that the cysteine protease cathepsin B might play a role in mediating the
pH-dependent activation of gelatinases. Cathepsin B expression in tumor-shed microvesicles was confirmed by
Western blot analysis and zymography. The activity of vesicle-associated cathepsin B measured using Z-Arg-
Arg-pNA as substrate was significantly increased at acidic pH values. Inhibition of protease activity by the cysteine
protease inhibitor, E-64, and treatment of ovarian cancer cells with small interfering RNA against cathepsin B sup-
pressed the ability of tumor-shed microvesicles to stimulate both gelatinase activation and the invasiveness of
endothelial cells observed at low pH values. We conclude that microvesicle shedding is a major secretory pathway
for cathepsin B release from tumor cells. Hence, the acidic microenvironment found in most solid tumors may
contribute to cathepsin B–mediated proinvasive capabilities of tumor-shed vesicles.
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Introduction
Mounting evidence suggests that cancer is a complex biologic system
affected by several factors that dampen or enhance the effects of
genetic alterations [1]. Hence, it has become increasingly apparent
that cancer is not a single-cell disease, and its growth, invasion,
and metastasis are constantly modulated by the host [2]; its micro-
environment, indeed, could exert a profound influence on the fate of
potentially neoplastic cells [3]. In general, tumor-environment inter-
actions are mediated by secreted growth factors, chemokines, cyto-
kines, and cell-to-cell adhesion contacts. However, there has been a
growing interest in a particular form of cell-to-cell communication
that involves shed membrane microvesicles.
Shedding of membrane-derived microvesicles is a physiological
phenomenon that accompanies cell activation and growth [4].
Intriguingly, tumor cells constitutively release microvesicles, trans-
porting a broad array of biologically active molecules, including cell
surface receptors, matrix metalloproteases, and adhesion molecules
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[5,6]. Tumor-shed vesicles have been implicated in a range of differ-
ent biologic processes including regulation of tumor invasiveness
and metastasis [5,7–11], drug resistance [12], and modulation of
the host immune response [13–15]. In addition, numerous reports
have shown that shed tumor vesicles may promote endothelial cell
migration, invasion, and neovascularization [16–20].
The tumor-promoting activities of membrane-shed vesicles are
modulated by the extracellular environment. In this regard, we have
recently shown that the bioavailability of angiogenic factors released
by tumor-shed vesicles depends on vesicle rupture induced by acidic
pH in the microenvironment [19]. It remains unclear, however,
whether the vesicle-mediated promotion of endothelial cells invasive-
ness could occur in a pH-dependent fashion.
Another mechanism whereby tumor-shed vesicles may exert their
proinvasive abilities can involve the activity of vesicle-associated pro-
teases [7,9], which in turn might be influenced by the pH of the
tumor microenvironment.
Cathepsins are cysteine proteinases that primarily function as
endopeptidases within endolysosomal compartments in normal cells;
they are involved in physiological processes such as protein turnover,
bone remodeling, reproduction, keratinocyte differentiation, and
apoptosis [21,22]. Multiple mechanisms increase cathepsins’ expres-
sion in tumors and in tumor-associated cells, including genetic am-
plification or alternative splicing [21]. In tumors, cysteine proteinases
can be secreted, bound to cell membrane, or released by shedding
vesicles [23].
Cathepsin B is highly upregulated in several malignant cells at the
mRNA, protein, and activity levels [21,24]. Notably, cathepsin B
activity is the result of several levels of regulation, including tran-
scription, posttranscription processing, translation, and glycosylation
[25,26]. Additionally, cathepsin B has been shown to facilitate direct
degradation of extracellular matrix (ECM) proteins [21] and acti-
vate other proteases capable of degrading ECM [27,28]. Although
both extracellular and intracellular forms of cathepsin B in tumor
cells are thought to play a major role in the degradation of ECM
[29,30], the secretory pathways for cathepsin B release from tumor
cells remain poorly understood; therefore, the mechanisms by which
cathepsin B could activate the other nonacid-dependent gelatinases is
not only poorly described but also controversial.
This study was designed to investigate the molecular mediators
of the pH-dependent proinvasive activity of tumor-shed vesicles.
Specifically, we investigated whether the cysteine protease cathep-




The CABA I cell line was established from the ascitic fluid of a
patient with ovarian carcinoma before any drug treatment [31]. Cells
were grown as monolayers in RPMI 1640 (Euroclone, Devon, UK)
with 5% fetal calf serum, 2 mM glutamine, penicillin and streptomy-
cin. Human umbilical vein endothelial cells (HUVECs) were isolated
from umbilical cord veins and grown on 1% gelatin-coated flasks in
DMEM supplemented with 10% fetal calf serum, 10% newborn calf
serum, 20 mM HEPES, 6 U/ml heparin, 2 mM glutamine, 50 μg/ml
endothelial cell growth factor (crude extract from bovine brain), pen-
icillin, and streptomycin. Cells from the third to fifth passages of cul-
ture were used.
Isolation of Membrane Vesicles from
Cell-Conditioned Medium
Vesicles were prepared as previously described [4]. Conditioned
medium obtained as above was centrifuged at 600g for 15 minutes
and then at 1500g for 15 minutes to remove cells and large debris.
Supernatants were centrifuged at 100,000g for 1 hour at 4°C. Vesi-
cles were quantified based on measurements of vesicle-associated pro-
tein levels using the method of Bradford (Bio-Rad, Milan, Italy),
with bovine serum albumin (Sigma, St. Louis, MO) as standard.
Pelleted microvesicles were resuspended in citrate-phosphate buffer
at three different pH values (5.6, 6.0, and 7.4) and were incubated for
30 minutes; after incubation, the acidic pH was made to neutral pH
value diluting vesicles in a convenient volume of RPMI 1640; mea-
surements of pH was controlled using pH indicator sticks. Each ex-
periment was conducted with or without cathepsin B inhibitors.
Motility and Invasion Assay
Endothelial cell invasion was assayed using modified Boyden
chambers with polycarbonate polyvinyl pyrrolidone–free Nucleopore
filters (pore size, 8 μm) [32]. Vesicles, added at the indicated concen-
trations to the upper compartment of the chamber, were used as ex-
ternal stimuli. Buffer alone or conditioned medium from NIH3T3
cells were used as negative and positive reference controls, respec-
tively. For motility (chemotaxis), filters were coated with 0.1%
gelatin. For invasion, filters were coated with a thick layer of the
reconstituted basement membrane Matrigel (Beckton Dickinson,
Bedford, MA; 0.5 mg/ml) which cells must degrade to migrate
through the filter. Human umbilical vein endothelial cells were
detached, washed in DMEM–0.1% bovine serum albumin, resus-
pended in the same medium at a concentration of 5 × 105/ml,
and added to the upper compartment of the chamber. After 4 hours
(motility) or 6 hours (invasion), filters were stained with Diff-Quik
(Baxter, Dudingen, Switzerland), and the migrated cells in five high-
power fields were counted.
Gelatin Zymography
Gelatin zymography was performed using sodium dodecyl sulfate–
polyacrylamide gels (SDS-PAGE, 7.5%) copolymerized with 1 mg/ml
gelatin type B (Sigma). After resuspension and incubation in the
specific buffer, vesicles (2–16 μg) were diluted in SDS-PAGE sam-
ple buffer in nonreducing conditions without heating. After electro-
phoresis, gels were washed twice for 30 minutes in 2.5% Triton
X-100 at room temperature and were incubated overnight in colla-
genase buffer (50 mM Tris–HCl, pH 7.4, containing 5 mM CaCl2
and 120 mM NaCl) at 37°C. Gels were stained with Coomassie Blue
R 250 (Bio-Rad) using a mixture of methanol–acetic acid–water
(4:1:5) for 1 hour and were destained in the same solution without
dye. Gelatinases’ activities were visualized as distinct bands, indi-
cating proteolysis of the substrate. The supernatant of HT1080
fibrosarcoma cells was used as a reference standard for matrix metal-
loproteinases 2 and 9 (MMP-2 and MMP-9). The broad-spectrum
cysteine protease inhibitor E-64 (0–50 μM; Bachem, Bubendorf,
Switzerland) was used to analyze the effect of cathepsin B inhibition
on the activation of gelatinases.
Western Blot Analysis
Vesicles (20 μg) from CABA I cells were resolved by sodium do-
decyl sulfate–12.5% polyacrylamide gel electrophoresis (SDS-PAGE)
under nonreducing conditions and were transferred to nitrocellulose
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membranes (Schleicher & Schuell, Dassel, Germany). Nonspecific
binding sites were blocked by overnight incubation with 10% nonfat
dry milk in TBS-T containing 0.5% Tween-20. Blots were incubated
with antibodies against human cathepsin B (1:2500 dilution of anti–
cathepsin B; Biomol, Plymouth Meeting, PA) for 1 hour, followed
by peroxidase-conjugated secondary antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA), in blocking buffer. After washing, reactive
bands were visualized using a chemiluminescence detection kit (ECL;
Amersham-Pharmacia, Uppsala, Sweden).
Cysteine Protease Zymography
Cysteine protease activity (cathepsins B and L) was detected by
SDS-PAGE using gels copolymerized with gelatine (0.3 mg/ml).
Samples were mixed with nonreducing SDS sample buffer and were
subjected to SDS-PAGE (12.5% acrylamide). After electrophoresis
and washing (50 mM sodium acetate pH 5.5, 100 mM sodium chlo-
ride, 10 mM cysteine, 2.5% Triton X-100), gels were incubated in
acetate buffer 50 mM (pH 4.8) containing 20 mM cysteine and
1 mM EDTA for 20 hours at 37°C.
The nature of the gelatinolytic activity was defined by using the
broad-spectrum cysteine protease inhibitor E-64 (50 μM in acetate
buffer). To distinguish the gelatinolytic activity due to cathepsin B
activity, the cathepsin L inhibitor Z-FY-CHO (Calbiochem, San
Diego, CA) was used.
Cathepsin B Activity Assay
Cathepsin B activity in vesicles or cell extracts was determined using
a spectrophotometric assay. The specific cathepsin B substrate, Z-Arg-
Arg-pNA (Biomol), was used. Substrate hydrolysis was monitored by
following the absorbance variation at 38°C, using a lambda 19 spectro-
photometer (Perkin-Elmer, Rahway, NJ) equipped with thermostatically
controlled cells. The reaction was spectrophotometrically recorded at
405 nm. Z-Arg-Arg-pNAwas monitored at 405 nm using two different
buffer systems: 1) 50 mM sodium acetate pH 5.5 containing 2.5 mM
DTT and 2.5 mM EDTA; and 2) 0.1% Triton X-100 or PBS pH 7.4
containing the same additives. A change in the extinction coefficient of
+8800/M per centimeter was used to compute units of enzyme activity.
A total of 500 μl of reaction buffer containing 5 to 20 μM substrate was
preincubated for 5 minutes before the addition of either cathepsin B
purified from human liver (Biomol) for reference, tumor-shed vesicles,
or of protein extracts from the CABA I cell lines. The reaction was
monitored for 15 minutes. All measurements were done at least in trip-
licate in different vesicle or protein extract preparations.
For the inhibition experiments, we used the selective cell-impermeable
cathepsin B inhibitor CA-074 (20 μM) [33], the cell-permeable
cathepsin B inhibitor CA-074Me (20 μM) [34], and the broad-
spectrum cysteine protease inhibitor E-64 (20 μM). All inhibitors
were obtained from Bachem.
Cathepsin B Gene Silencing
We silenced cathepsin B by using cathepsin B small interfering
RNA (siRNA) (h) sc-29238, with scrambled oligos sc-37007 as con-
trol and sc-29528 siRNA transfection reagents (Santa Cruz Bio-
technology) according to the manufacturer’s protocol. Briefly, the
cells were incubated overnight at 37°C in medium without anti-
biotics, treated according to the transfection protocol, and then in-
cubated for 6 hours at 37°C. At the end of incubation, the medium
containing twice the amount of normal serum and antibiotics was
added. After an incubation period of 72 hours, reverse transcription–
polymerase chain reaction (RT-PCR), cathepsin B zymography, and
Western blot analysis were performed to confirm that the CABA I
cell transfection was successful. The same results were obtained
with nonsilenced CABA I cells transfected with scrambled oligos and
CABA I wild-type.
Real-Time PCR for Cathepsin B
Total RNA was isolated using SV Total RNA Isolation System
(Promega, Madison, WI), and cDNA was synthesized from 5 μg
RNA using the ImProm-II Reverse Transcription System (Promega)
according to the manufacturer’s protocol. Each real-time PCR re-
action was prepared in triplicate and contained 2.0 μl of cDNA.
Polymerase chain reaction was carried out using SYBR-green detec-
tion of PCR products in real-time (Roche Diagnostics, Indianapolis,
IN). The sequences of the primers used for PCR were as follows:
cathepsin B forward, 5′-CCAGGGAGCAAGACAGAGAC-3′, re-
verse 5′-GAGACTGGCGTTCTCCAAAG-3′ (163 bp); GADPH
forward 5′-GGCCTCCAAGGAGTAAGACC-3′, GADPH reverse
5′-AGGGGTCTACATGGCAACTG-3′ (147 bp). A comparative
ΔCt method was used to determine gene expression. Expression levels
were normalized to the expression levels of the housekeeping gene
GADPH. To determine the relative expression level of cathepsin B,
the expression in CABA I cells was arbitrarily set at 1.
Statistical Analysis
All data shown are from at least three independent experiments
and are expressed as mean ± SD. Statistical significance was deter-
mined by using the Mann-Whitney U test. Calculations were per-
formed using GraphPad Prism 4 software (GraphPad, San Diego,
CA). Statistical significance was set at P < .05.
Results
Endothelial Cell Invasiveness Is Increased By Tumor-Shed
Vesicles Exposed to Acidic pH
We have previously shown that acidic pH increases the chemo-
tactic and proinvasive activities of tumor-shed membrane vesicles
[19]. The chemotactic activity was mainly due to the vascular endo-
thelial growth factor (VEGF) released from microvesicles; it was pre-
viously demonstrated that transient exposure to low extracellular pH
induces an increased steady-state level of VEGF mRNA expression,
which correlates with prolonged VEGF mRNA stability and rise in
VEGF secretion [35].
However, little is known about the molecular mediators involved
in the increased proinvasive activity. To determine whether the ability
of tumor-shed vesicles to stimulate endothelial cell invasiveness may
occur in a pH-dependent fashion, in this study, we used the CABA I
cell model. These cells have the capacity to release membrane vesi-
cles that stimulate endothelial cell motility and invasiveness [19].
Differently from other cell models [19], the exposure of CABA I–
shed vesicles to acidic pH (6.0 and 5.6) increased their proinvasive
activity (Figure 1A), with no effect on their chemotactic activity
(Figure 1B). We therefore selected CABA I cells as a means to inves-
tigate the effect of pH on the proinvasive activity of vesicles, indepen-
dently from the effect on pure motility.
Differently from pure motility, invasiveness requires enzymatic
degradation of ECM. We thus investigated whether acidic pH could
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influence the activity of MMP-2 and MMP-9 in CABA I–shed vesi-
cles. To achieve this goal, vesicles isolated from CABA I–conditioned
medium were exposed at three different pH values (5.6, 6.0, and 7.4)
and were subsequently analyzed by gelatin zymography. The pattern of
the lytic bands is shown in Figure 1C. Bands corresponding to the
activated forms of MMP-2 and MMP-9 were more evident at acidic
pH (5.6) compared to pH 7.4. Unexpectedly, bands of lysis
corresponding to the proenzyme forms of MMP-2 and MMP-9 were
both more marked at lower pH values. These findings indicate that
acidic pH is involved in the activation of vesicle-associated gelatinases
which, in turn, may promote endothelial cell invasiveness.
Presence of Cathepsin B in Shed Vesicles
In the light of these results, we reasoned that the cysteine protease
cathepsin B, whose activity is acidic pH-dependent [36], might play
a role in mediating activation of vesicle-associated gelatinases. Firstly,
we asked whether vesicles from CABA I cells contained cathepsin B.
In keeping with our hypothesis, Western blot analysis demonstrated
the presence of cathepsin B in shed membrane vesicles. Notably, the
vesicle-associated forms of cathepsin B were different from those found
in cell extracts (Figure 2A). Accordingly, cell extracts showed bands with
molecular masses of 15 to 30 kDa corresponding to those of the active
enzyme, whereas shed vesicles showed a band with a molecular mass of
41 kDa corresponding to the zymogen (proform) of cathepsin B.
Figure 1. Effect of tumor-shed vesicles on endothelial cell motility and invasiveness. Human umbilical vein endothelial cell invasiveness
(A) and motility (B) were tested in the Boyden chamber. Vesicles shed by human ovarian carcinoma cells CABA I were used as external
stimuli. Data (mean ± SD of three independent experiments) represent the number of cells that had migrated in five high-power fields
expressed in percentage, counting untreated cells as 100%, P < .05. (C) Effect of acidic pH on vesicle-associated gelatinases.
Figure 2. Presence of cathepsin B in CABA I–shed vesicles. (A)
Western blot analysis of cell extracts and vesicle-associated cathep-
sin B. (B) Cysteine zymography of extracts and vesicle-associated
cathepsins B and L. The identification of cathepsin B was confirmed
through the inhibition of cathepsin L (not shown).
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Cathepsin B activity in CABA I vesicles and extracts was detected by
means of cathepsin B gelatin zymography; because both cathepsins (B
and L) are detected by means of this technique, we confirmed the iden-
tity of the bands as cathepsin B by using a selective cathepsin L inhibitor
(data not shown). In keeping with the results of Western blot analysis,
the active forms of cathepsin Bwere detected in CABA I extracts as bands
of gelatinolysis with molecular masses of 15 to 30 kDa. In contrast, no
gelatinolytic activity was detected in CABA I–shed vesicles (Figure 2B).
This result was not surprising given the absence of procathepsin B ac-
tivity in this assay. In addition, gelatinase activity in cells’ extracts was
completely ablated by the general cysteine proteinase inhibitor, E-64,
thereby confirming identification of cathepsins (data not shown).
We then investigated whether acidic pH could influence the ac-
tivity of cathepsin B in CABA I–shed vesicles and cell extracts. To
achieve this goal, cathepsin B activity was measured in cell extracts
and vesicles exposed at two different pH values (5.6 and 7.4). Spe-
cifically, enzymatic activity was measured using Z-Arg-Arg-pNA as
substrate under different pH conditions (Table 1). Both the activity
and the stability of cathepsin B were assessed. The results showed
that vesicle-associated cathepsin B activity was increased 1300-fold
at acidic pH values compared to physiological pH 7.4. Similarly, ca-
thepsin B activity in cells’ extract was increased 33-fold at pH 5.6
versus pH 7.4. Cleavage was completely inhibited by E-64. A mod-
erate inhibition was seen with the use of cathepsin B inhibitors CA-
074 and CA-074Me (data not shown).
Role of Cathepsin B in the pH-Dependent Proinvasive
Activity of Vesicles
To investigate the role of cathepsin B in mediating vesicle-induced
endothelial invasiveness observed at low pH values, we followed two
distinct experimental approaches.
Vesicles collected from CABA I cells were incubated in pH 5.6 and
pH 7.4 buffer, either with or without E-64 (50 μM), and were tested
for their ability to induce endothelial cells’ invasiveness (Figure 3A).
Vesicles incubated at pH 5.6 showed an increased proinvasive activity
compared to vesicles incubated at pH 7.4. The pH-dependent in-
crement in the proinvasive activity of tumor-shed vesicles was com-
pletely abrogated by the typical cysteine protease inhibitor E-64.
After exposure to E-64, endothelial cells’ invasiveness induced by ves-
icles was similar to that observed at physiological pH. These findings
indicate that cysteine cathepsins play a critical role in the biologic
activity of tumor-shed vesicles at acidic pH. Conversely, cathepsins
are not critically involved in the biologic activity of tumor-shed ves-
icles at physiological pH. Accordingly, E-64 had only a marginal ef-
fect on vesicle-induced endothelial cell invasiveness at pH 7.4.
To verify whether cathepsins may be responsible for the pH-
dependent modulation of vesicle gelatinases, vesicles shed by CABA I
cells were resuspended in buffer at pH 5.6 in the presence of E-64
(0–50 μM). We subsequently analyzed the lytic bands by means of gel-
atin zymography (Figure 3B). In the presence of the cysteine inhibitor
E-64, the bands corresponding to activated MMP-2 and MMP-9 were
not detectable. Moreover, E-64 appeared to modulate the activity of the
proenzymatic forms of both gelatinases. Accordingly, fainter bands were
discernible in the presence of E-64.
To evaluate the role of one specific cysteine protease, cathepsin B,
CABA I cells were transfected with a specific siRNA against cathep-
sin B to silence its expression. Silencing was confirmed by the use of
real-time PCR, Western blot analysis, and by zymography studies.
RT-PCR analysis showed a ∼10-fold reduction in target mRNA com-
pared to control cells (Figure 4A). Western blot analysis showed three
different forms (15, 20, and 30 kDa) in extracts from control cells
Table 1. Vesicles- and Cell Extracts–Associated Enzymatic Activity.
Enzymatic Activity (mol/min × mg protein)
pH 7.4 pH 5.6
Cell extracts 5.7 × 10−10 ± 2.8 × 10−11* 1.9 × 10−8 ± 9.5 × 10−10*
Vesicles 6.1 × 10−10 ± 3 × 10−11* 7.9 × 10−7 ± 3.9 × 10−8*
Data are the mean ± SD of three independent experiments.
*P < .05.
Figure 3. Effect of cathepsin B inhibition. (A) Vesicles shed from CABA I were isolated and tested for their ability to stimulate HUVEC
invasiveness at pH 5.6 and 7.4, either with or without the cysteine proteinase inhibitor E-64 (50 μM). Data (mean ± SD of three inde-
pendent experiments) represent the number of cells that had migrated in five high-power fields expressed in percentage, counting
untreated cells as 100%, P < .05. (B) Zymographic analysis of vesicle-associated gelatinases incubated with inhibitor E-64 0 to 50 μM.
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compared to two different forms (20 and 30 kDa) in extracts from
silenced cells. These two bands appeared less intense compared to
control bands (Figure 4B). Similarly, gelatin zymography showed
three different forms (15, 20, and 30 kDa) in extracts from parental
CABA I compared to two different forms (20 and 30 kDa) in extracts
from silenced cells. These two bands appeared less intense compared
to control bands (Figure 4C ).
As expected, microvesicles shed by CABA I cells with silenced ca-
thepsin B showed no enzymatic activity as determined by the Z-Arg-
Arg-pNA substrate (data not shown). Microvesicles isolated from
Figure 4. Effectiveness of cathepsin B siRNA silencing in CABA I cells. (A) RT-PCR analysis of parental control and silenced CABA I cells.
(B) Western blot analysis of cathepsin B in cellular extracts. (C) Cysteine zymography of cathepsins B and L in cellular extracts.
Figure 5. Effect of cathepsin B gene silencing. (A) Vesicles shed from CABA I cells, either parental control and silenced, were isolated
and tested for their ability to stimulate HUVEC invasiveness at pH 5.6. Data (mean ± SD of three independent experiments) represent
the number of cells that had migrated in five high-power fields expressed in percentage, counting untreated cells as 100%, P < .05. (B)
Zymographic analysis of vesicle-associated gelatinases.
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CABA I cells with silenced cathepsin B expression were less effective
inducers of proinvasive activity in HUVECs compared to parental
cell–derived microvesicles at pH 5.6 (Figure 5A).
We then investigated whether cathepsin B silencing may affect
gelatinase activity in CABA I–shed microvesicles at pH 5.6. The
pattern of the lytic bands detected after zymography is presented
in Figure 5B. Bands for both the proenzymatic forms of MMP-2
and MMP-9 were less intense in vesicles isolated from CABA I cells
with silenced cathepsin B. Additionally, bands corresponding to the
active forms of gelatinases were not detectable. Altogether, these find-
ings confirmed a crucial role of cathepsin B in mediating gelatinases’
activation in a pH-dependent fashion.
Discussion
In recent years, growing interest has been focused on tumor-
released microvesicles in the light of their ability to transport a wide
array of biologically active molecules involved in malignant trans-
formation and/or progression [10,12,13,37–39]. It has been thus
hypothesized that tumor-shed vesicles may deliver detrimental sig-
nals to the tumor microenvironment independently from direct cell-
to-cell contact [9]. Accordingly, tumor-shed microvesicles may bear
cell surface receptors, adhesion molecules, and metalloproteinases,
thereby modulating the tumor-invasive capabilities and promoting
tumor angiogenesis [4,16–18].
We have recently demonstrated that tumor-shed vesicles transport
VEGF and that the bioavailability of angiogenic factor depends
on vesicle rupture induced by acidic pH in the microenvironment
[19]. Of interest, the extracellular pH in solid tumors is generally
acidic because of elevated anaerobic glycolysis and impaired clearance
of acidic metabolic wastes [40]. Acidification of extracellular environ-
ment is advantageous to the tumor because it promotes angiogenesis
through acid-induced release of VEGF and because, indirectly, pro-
motes ECM degradation by inducing adjacent normal cell (such as
fibroblasts and macrophages) to release proteolytic enzymes such as
cathepsin B [41]. Therefore, the release of vesicle-associated VEGF
triggered by low pH values suggests that the activity of tumor-shed
vesicles may be regulated by the tumor microenvironment in a pH-
dependent fashion.
Our current findings indicate that low pH may promote the in-
vasive capacities of tumor-shed vesicles. Although acidic pH did not
increase the chemotactic activity of CABA I–shed vesicles, we have
demonstrated that the exposure of shed vesicles to acidic medium
(pH 6.0 and 5.6) increased the ability of tumor vesicles to promote
endothelial cell invasiveness. Because MMP-2 and MMP-9 activities
were increased in tumor-shed vesicle after exposure to acidic me-
dium, we reasoned that the cysteine protease cathepsin B might play
a role in mediating the pH-dependent activation of gelatinases.
The lysosomal cysteine protease cathepsin B is implicated in the
degradation of ECM, a critical step in tumor dissemination and angio-
genesis. Cathepsin B has a pH optimum of 4.5 to 5.5 and has been
shown to lose its activity at neutral pH [42]. Of interest, it has been
previously demonstrated that cathepsin B appears to undergo auto-
degradation at neutral pH [43]. Vesicles shed by CABA I cells appear
to contain the inactive proenzyme of cathepsin B, as demonstrated by
Western blot analysis. However, this technique has a low sensitivity for
detecting the presence of small amounts of active mature cathepsin B,
whose presence is demonstrated by a more sensitive enzymatic activity
assay. Additionally, acidic conditions were shown to increase the activ-
ity of cathepsin B in tumor-shed microvesicles, thereby suggesting an
ability of this enzyme to increase invasiveness in a pH-dependent man-
ner. Unexpectedly, we found a higher cathepsin B activity in
tumor-shed vesicles compared to total cell extracts. This finding sug-
gests that microvesicles hijack cathepsin B as a means to promote ma-
lignant progression.
There are at least two lines of evidence supporting a crucial role for
vesicle-associated cathepsin B in mediating pH-dependent tumor in-
vasiveness. Firstly, the synthetic cysteine protease inhibitor E-64 was
shown to diminish the activity of vesicle-associated gelatinases and to
reduce the ability of tumor-shed microvesicles to induce endothelial
cells’ invasiveness at neutral pH. Moreover, vesicles shed by ovarian
carcinoma cell line CABA I with silenced cathepsin B expression
had reduced proinvasive ability and diminished activity of gelatinases
compared to parental cell–derived microvesicles.
Cathepsin B may contribute to invasiveness in ovarian cancer by
various direct and indirect mechanisms. The proteolytic activity of
cathepsin B facilitates direct degradation of several ECM proteins,
including fibronectin, laminin, tenascin C, and type IV collagen
[44]. Moreover, cathepsin B can indirectly promote invasiveness by
activating other matrix-degrading proteolytic systems such as MMPs
and urokinase-type plasminogen activator [27] and by promoting
degradation of tissue inhibitors of metalloproteinases [28]. Interest-
ingly, hereto we have shown that cathepsin B may play a role in pro-
moting the pH-dependent expression of the proenzymatic forms of
MMP-2 and MMP-9. Future studies are needed to further clarify the
mechanisms whereby this phenomenon occurs. In any case, the effect
of vesicle-associated cathepsin B appears subjected to low pH values,
as shown by the poor inhibitory activity on vesicle-induced invasive-
ness exerted by E-64 at physiological pH. This finding is in agree-
ment with the acidic pH optimum for cathepsin B peptidase activity.
Altogether, our results indicate that cathepsin B may be carried
within CABA I–shed vesicles. In addition, it is posited that an
amount of vesicle-associated cathepsin B pool may be active in con-
ditions of acidic pH typical of tumor settings. Alternatively, cathepsin
B may be released from tumor-shed vesicles in an inactive form that
can be activated by proteolytic processing [45], autocatalytic pro-
cathepsin B cleavage [36,46], or through interaction with cell surface
glycosaminoglycans [21].
In conclusion, we have demonstrated that tumor-shed micro-
vesicles may induce proangiogenic activities of endothelial cells by
a cathepsin B–mediated mechanism. The tumor-promoting activities
of vesicle-associated cathepsin B may be activated in conditions of
acidic pH typical of tumor microenvironment.
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